IL158765A0 - Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors - Google Patents

Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Info

Publication number: IL158765A0
Authority: IL; Israel
Prior art keywords: self; transfer protein; cholesteryl ester; protein inhibitors; ester transfer
Prior art date: 2001-06-21

Application number

IL15876502A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-21

Filing date

2002-05-03

Publication date

2004-05-12

2002-05-03 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-05-12 Publication of IL158765A0 publication Critical patent/IL158765A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Colloid Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Peptides Or Proteins (AREA)

IL15876502A 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors IL158765A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30002801P	2001-06-21	2001-06-21
PCT/IB2002/001571 WO2003000295A2 (en)	2001-06-21	2002-05-03	Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Publications (1)

Publication Number	Publication Date
IL158765A0 true IL158765A0 (en)	2004-05-12

Family

ID=23157363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15876502A IL158765A0 (en)	2001-06-21	2002-05-03	Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Country Status (33)

Country	Link
US (2)	US6962931B2 (bg)
EP (1)	EP1453544A2 (bg)
JP (1)	JP2005500314A (bg)
KR (1)	KR20040015746A (bg)
CN (1)	CN1635911A (bg)
AP (1)	AP2002002559A0 (bg)
AR (1)	AR034599A1 (bg)
BG (1)	BG108486A (bg)
BR (1)	BR0210505A (bg)
CA (1)	CA2455288A1 (bg)
CR (1)	CR7163A (bg)
CZ (1)	CZ20033341A3 (bg)
EA (1)	EA200301139A1 (bg)
EC (1)	ECSP034875A (bg)
EE (1)	EE200400024A (bg)
GT (1)	GT200200124A (bg)
HN (1)	HN2002000153A (bg)
HU (1)	HUP0400263A2 (bg)
IL (1)	IL158765A0 (bg)
IS (1)	IS7014A (bg)
MA (1)	MA27034A1 (bg)
MX (1)	MXPA04000014A (bg)
NO (1)	NO20035632L (bg)
OA (1)	OA12619A (bg)
PA (1)	PA8548601A1 (bg)
PE (1)	PE20030128A1 (bg)
PL (1)	PL368850A1 (bg)
SK (1)	SK15172003A3 (bg)
SV (1)	SV2003001103A (bg)
TN (1)	TNSN03139A1 (bg)
UY (1)	UY27344A1 (bg)
WO (1)	WO2003000295A2 (bg)
ZA (1)	ZA200308561B (bg)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7026290B1 (en) *	1998-12-30	2006-04-11	Dexcel Ltd.	Dispersible concentrate for the delivery of cyclosprin
US7732404B2 (en) *	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
JP4031232B2 (ja) *	2001-11-09	2008-01-09	カプスゲル・ジャパン株式会社	新規カプセル
EP1469832B2 (en) *	2002-02-01	2016-10-26	Bend Research, Inc.	Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AU2003219942A1 (en) *	2002-03-01	2003-09-16	Cesi Chemical, A Flotek Company	Composition and process for well cleaning
US20040175341A1 (en) *	2003-03-04	2004-09-09	Manning Monna Marie	Microemulsion for cosmetic or pharmaceutical use containing an active ingredient
CN1777419B (zh) *	2003-03-17	2010-04-28	日本烟草产业株式会社	Cetp抑制剂的药物组合物
CA2519458A1 (en)	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
US20040225018A1 (en) *	2003-03-17	2004-11-11	Japan Tobacco Inc.	Pharmaceutical compositions of CETP inhibitors
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
JP2007501218A (ja) *	2003-08-04	2007-01-25	ファイザー・プロダクツ・インク	非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
MXPA06003499A (es) *	2003-09-30	2006-06-08	Pfizer Prod Inc	Inhibidores de proteina de transferencia de esteres de colestrerilo y sus metabolitos.
KR20060085675A (ko) *	2003-10-08	2006-07-27	일라이 릴리 앤드 캄파니	이상지혈증 치료를 위한 화합물 및 방법
US20050220866A1 (en) *	2004-04-02	2005-10-06	Dr. Reddy's Laboratories Limited	Novel capsule formulations of etoposide for oral use
US7700774B2 (en)	2004-12-20	2010-04-20	Dr. Reddy's Laboratories Ltd.	Heterocyclic compounds and their pharmaceutical compositions
CA2605214C (en)	2004-12-31	2016-07-12	Reddy Us Therapeutics, Inc.	Benzylamine derivatives as cetp inhibitors
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006085217A2 (en) *	2005-02-08	2006-08-17	Pfizer Products Inc.	Solid adsorbates of hydrophobic drugs
US7623458B2 (en) *	2005-09-30	2009-11-24	The Boeing Company	System and method for providing integrated services across cryptographic boundaries in a network
EP1965764B1 (en) *	2005-12-05	2011-07-13	Merck Sharp & Dohme Corp.	Self-emulsifying formulations of cetp inhibitors
KR101164516B1 (ko) *	2005-12-31	2012-07-13	태슬리 파마슈티컬 그룹 컴퍼니 리미티드	양명아주 추출물을 함유하는 약학 조성물, 및 이의 제조방법 및 용도
EP2037909A2 (en) *	2006-06-30	2009-03-25	Schering Corporation	Solid dose formulations of a thrombin receptor antagonist
EP1961412A1 (en)	2006-12-27	2008-08-27	LEK Pharmaceuticals D.D.	Self-microemulsifying drug delivery systems
US9222013B1 (en)	2008-11-13	2015-12-29	Cesi Chemical, Inc.	Water-in-oil microemulsions for oilfield applications
MX2011005304A (es) *	2008-12-08	2011-06-01	Hoffmann La Roche	Administracion combinada de farmaco.
US20100273730A1 (en) *	2009-04-27	2010-10-28	Innopharmax, Inc.	Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
SG195015A1 (en) *	2011-05-20	2013-12-30	Aventis Pharma Inc	Pharmaceutical composition comprising fexofenadine
CN103827105B (zh)	2011-08-18	2016-08-17	雷迪博士实验室有限公司	作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物
KR101803866B1 (ko)	2011-09-27	2017-12-04	닥터 레디스 레보러터리즈 리미티드	동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
EP2768486B1 (en) *	2011-10-21	2018-10-03	First Tech International Limited	Tocotrienol compositions
US20130292121A1 (en)	2012-04-15	2013-11-07	Cesi Chemical, Inc.	Surfactant formulations for foam flooding
US9200192B2 (en)	2012-05-08	2015-12-01	Cesi Chemical, Inc.	Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US11407930B2 (en)	2012-05-08	2022-08-09	Flotek Chemistry, Llc	Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
WO2014128564A2 (en) *	2013-02-21	2014-08-28	Dr. Reddy's Laboratories Ltd.	Pharmaceutical compositions of cetp inhibitors
US9068108B2 (en)	2013-03-14	2015-06-30	Cesi Chemical, Inc.	Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10287483B2 (en)	2013-03-14	2019-05-14	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol
US10590332B2 (en)	2013-03-14	2020-03-17	Flotek Chemistry, Llc	Siloxane surfactant additives for oil and gas applications
US9884988B2 (en)	2013-03-14	2018-02-06	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US10717919B2 (en)	2013-03-14	2020-07-21	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US9428683B2 (en)	2013-03-14	2016-08-30	Flotek Chemistry, Llc	Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10577531B2 (en)	2013-03-14	2020-03-03	Flotek Chemistry, Llc	Polymers and emulsions for use in oil and/or gas wells
US11180690B2 (en)	2013-03-14	2021-11-23	Flotek Chemistry, Llc	Diluted microemulsions with low surface tensions
US10421707B2 (en)	2013-03-14	2019-09-24	Flotek Chemistry, Llc	Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US9321955B2 (en)	2013-06-14	2016-04-26	Flotek Chemistry, Llc	Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10000693B2 (en)	2013-03-14	2018-06-19	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US9868893B2 (en)	2013-03-14	2018-01-16	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US9464223B2 (en)	2013-03-14	2016-10-11	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
US10941106B2 (en)	2013-03-14	2021-03-09	Flotek Chemistry, Llc	Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US10053619B2 (en)	2013-03-14	2018-08-21	Flotek Chemistry, Llc	Siloxane surfactant additives for oil and gas applications
US11254856B2 (en)	2013-03-14	2022-02-22	Flotek Chemistry, Llc	Methods and compositions for use in oil and/or gas wells
CN104706586A (zh) *	2013-12-16	2015-06-17	天津迈迪瑞康生物医药科技有限公司	一种丁酸氯维地平脂肪乳浓缩液、其制备方法及用途
CN104706587A (zh) *	2013-12-16	2015-06-17	天津迈迪瑞康生物医药科技有限公司	一种依托咪酯脂肪乳浓缩液、其制备方法及用途
CN104706689A (zh) *	2013-12-16	2015-06-17	天津迈迪瑞康生物医药科技有限公司	一种鸦胆子油脂肪乳浓缩液、其制备方法及用途
US9890624B2 (en)	2014-02-28	2018-02-13	Eclipse Ior Services, Llc	Systems and methods for the treatment of oil and/or gas wells with a polymeric material
US9890625B2 (en)	2014-02-28	2018-02-13	Eclipse Ior Services, Llc	Systems and methods for the treatment of oil and/or gas wells with an obstruction material
CA2891278C (en)	2014-05-14	2018-11-06	Cesi Chemical, Inc.	Methods and compositions for use in oil and / or gas wells
US9957779B2 (en)	2014-07-28	2018-05-01	Flotek Chemistry, Llc	Methods and compositions related to gelled layers in oil and/or gas wells
SG11201703593PA (en)	2014-11-04	2017-06-29	Innopharmax Inc	Oral administration of unstable or poorly-absorbed drugs
CN104490775A (zh) *	2014-12-20	2015-04-08	长沙佰顺生物科技有限公司	一种安塞曲匹脂肪乳及其制备方法
CN104546710A (zh) *	2014-12-20	2015-04-29	长沙佰顺生物科技有限公司	一种安塞曲匹纳米乳及其制备方法
KR101590072B1 (ko) *	2014-12-23	2016-01-29	한미약품 주식회사	두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
EP3302429A1 (en)	2015-05-28	2018-04-11	Dr. Reddy's Laboratories Ltd.	Oral composition of celecoxib for treatment of pain
KR20180129943A (ko)	2016-04-15	2018-12-05	노비라 테라퓨틱스, 인코포레이티드	캡시드 조립 억제제를 포함하는 배합물 및 방법
US10934472B2 (en)	2017-08-18	2021-03-02	Flotek Chemistry, Llc	Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
WO2019108971A1 (en)	2017-12-01	2019-06-06	Flotek Chemistry, Llc	Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
MA52019A (fr)	2018-03-14	2021-01-20	Janssen Sciences Ireland Unlimited Co	Schéma posologique de modulateur d'assemblage de capside
SG11202105336TA (en) *	2018-11-26	2021-06-29	Hepion Pharmaceuticals Inc	Pharmaceutical formulations of cyclosporine analogs
TWI834862B (zh) *	2019-04-11	2024-03-11	美商ＲＰ先靈爾科技公司	用於經口投遞滲透性不良蛋白質、肽及小分子之調配物
CN110252395B (zh) *	2019-07-01	2020-10-16	湖北远大生命科学与技术有限责任公司	一种用于制备高纯度牛磺酸的催化剂及其应用
US11104843B2 (en)	2019-10-10	2021-08-31	Flotek Chemistry, Llc	Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency
FR3110852B1 (fr)	2020-05-27	2024-03-15	Centre Nat Rech Scient	Emulsions pour liberation controlee de medicaments
US11512243B2 (en)	2020-10-23	2022-11-29	Flotek Chemistry, Llc	Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods
CN114681470A (zh)	2020-12-28	2022-07-01	雷迪博士实验室有限公司	治疗疼痛的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE445174B (sv)	1978-03-07	1986-06-09	Sandoz Ag	Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
GB9208712D0 (en)	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
WO1995031979A1 (en)	1994-05-19	1995-11-30	R.P. Scherer International Corporation	Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
AU692255B2 (en)	1995-04-24	1998-06-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Self-emulsifiable formulation producing an oil-in-water emulsion
GB9608719D0 (en)	1996-04-26	1996-07-03	Scherer Ltd R P	Pharmaceutical compositions
US5993858A (en) *	1996-06-14	1999-11-30	Port Systems L.L.C.	Method and formulation for increasing the bioavailability of poorly water-soluble drugs
SI9720010B (sl)	1996-06-19	2009-10-31	Novartis Ag	Ciklosporin vsebujoči mehki kapsulni pripravki
US5958876A (en)	1996-06-19	1999-09-28	Novartis Ag	Cyclosporin-containing pharmaceutical compositions
JP2894445B2 (ja) *	1997-02-12	1999-05-24	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤として有効な化合物
AU9297798A (en) *	1997-09-16	1999-04-05	G.D. Searle & Co.	Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741399A1 (de) *	1997-09-19	1999-03-25	Bayer Ag	Tetrahydrochinoline
US6063762A (en)	1997-12-05	2000-05-16	Chong Kun Dang Corp.	Cyclosporin-containing microemulsion preconcentrate composition
WO1999041237A1 (en) *	1998-02-13	1999-08-19	G.D. Searle & Co.	Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
GT199900147A (es)	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) *	1998-09-17	2000-10-31	Pfizer Inc.	Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147090A (en)	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en)	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
EP1115694A1 (en) *	1998-09-25	2001-07-18	Monsanto Company	Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US7026290B1 (en)	1998-12-30	2006-04-11	Dexcel Ltd.	Dispersible concentrate for the delivery of cyclosprin
CO5271716A1 (es) *	1999-11-30	2003-04-30	Pfizer Prod Inc	Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US6482862B1 (en) *	1999-12-20	2002-11-19	G.D. Searle & Co.	Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity
US7115279B2 (en) *	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20030170309A1 (en) *	2001-06-22	2003-09-11	Babcock Walter C.	Pharmaceutical compositions containing polymer and drug assemblies
EP1269994A3 (en) *	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmaceutical compositions comprising drug and concentration-enhancing polymers
EP1401503B1 (en) *	2001-06-22	2007-05-09	Pfizer Products Inc.	Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
EP1404300B1 (en) *	2001-06-22	2009-09-30	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
EP1469832B2 (en) *	2002-02-01	2016-10-26	Bend Research, Inc.	Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
EP1469829B1 (en) *	2002-02-01	2016-01-27	Bend Research, Inc	Immediate release dosage forms containing solid drug dispersions
AU2003286372A1 (en) *	2002-12-20	2004-07-14	Pfizer Products Inc.	Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

2002
- 2002-05-03 WO PCT/IB2002/001571 patent/WO2003000295A2/en active Application Filing
- 2002-05-03 BR BR0210505-5A patent/BR0210505A/pt not_active IP Right Cessation
- 2002-05-03 OA OA1200300317A patent/OA12619A/en unknown
- 2002-05-03 TN TNPCT/IB2002/001571A patent/TNSN03139A1/fr unknown
- 2002-05-03 SK SK1517-2003A patent/SK15172003A3/sk not_active Application Discontinuation
- 2002-05-03 EE EEP200400024A patent/EE200400024A/xx unknown
- 2002-05-03 HU HU0400263A patent/HUP0400263A2/hu unknown
- 2002-05-03 CA CA002455288A patent/CA2455288A1/en not_active Abandoned
- 2002-05-03 EP EP02732994A patent/EP1453544A2/en not_active Withdrawn
- 2002-05-03 EA EA200301139A patent/EA200301139A1/ru unknown
- 2002-05-03 CZ CZ20033341A patent/CZ20033341A3/cs unknown
- 2002-05-03 JP JP2003506937A patent/JP2005500314A/ja active Pending
- 2002-05-03 KR KR10-2003-7016651A patent/KR20040015746A/ko not_active Application Discontinuation
- 2002-05-03 PL PL02368850A patent/PL368850A1/xx not_active Application Discontinuation
- 2002-05-03 IL IL15876502A patent/IL158765A0/xx unknown
- 2002-05-03 MX MXPA04000014A patent/MXPA04000014A/es active IP Right Grant
- 2002-05-03 CN CNA028124820A patent/CN1635911A/zh active Pending
- 2002-06-19 AR ARP020102297A patent/AR034599A1/es unknown
- 2002-06-19 PE PE2002000528A patent/PE20030128A1/es not_active Application Discontinuation
- 2002-06-19 GT GT200200124A patent/GT200200124A/es unknown
- 2002-06-19 US US10/175,643 patent/US6962931B2/en not_active Expired - Fee Related
- 2002-06-20 AP APAP/P/2002/002559A patent/AP2002002559A0/en unknown
- 2002-06-20 HN HN2002000153A patent/HN2002000153A/es unknown
- 2002-06-20 UY UY27344A patent/UY27344A1/es not_active Application Discontinuation
- 2002-06-20 SV SV2002001103A patent/SV2003001103A/es not_active Application Discontinuation
- 2002-06-20 PA PA20028548601A patent/PA8548601A1/es unknown
2003
- 2003-10-31 IS IS7014A patent/IS7014A/is unknown
- 2003-11-03 ZA ZA200308561A patent/ZA200308561B/xx unknown
- 2003-11-24 CR CR7163A patent/CR7163A/es not_active Application Discontinuation
- 2003-12-03 EC EC2003004875A patent/ECSP034875A/es unknown
- 2003-12-10 MA MA27430A patent/MA27034A1/fr unknown
- 2003-12-17 NO NO20035632A patent/NO20035632L/no not_active Application Discontinuation
- 2003-12-22 BG BG108486A patent/BG108486A/bg unknown
2005
- 2005-09-08 US US11/222,908 patent/US20060014788A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AP2002002559A0 (en)	2002-06-30
JP2005500314A (ja)	2005-01-06
CA2455288A1 (en)	2003-01-03
PL368850A1 (en)	2005-04-04
CR7163A (es)	2004-02-23
BR0210505A (pt)	2004-05-18
US20030022944A1 (en)	2003-01-30
US20060014788A1 (en)	2006-01-19
HN2002000153A (es)	2002-11-05
ZA200308561B (en)	2004-11-17
OA12619A (en)	2006-06-12
EA200301139A1 (ru)	2004-12-30
EP1453544A2 (en)	2004-09-08
IS7014A (is)	2003-10-31
PA8548601A1 (es)	2003-09-05
KR20040015746A (ko)	2004-02-19
US6962931B2 (en)	2005-11-08
SV2003001103A (es)	2003-03-18
NO20035632D0 (no)	2003-12-17
MA27034A1 (fr)	2004-12-20
PE20030128A1 (es)	2003-02-28
AR034599A1 (es)	2004-03-03
TNSN03139A1 (fr)	2005-12-23
MXPA04000014A (es)	2004-05-21
ECSP034875A (es)	2004-01-28
NO20035632L (no)	2004-02-18
UY27344A1 (es)	2003-01-31
GT200200124A (es)	2003-09-22
WO2003000295A3 (en)	2004-05-27
BG108486A (bg)	2005-03-31
CZ20033341A3 (cs)	2004-10-13
HUP0400263A2 (hu)	2005-03-29
SK15172003A3 (en)	2004-11-03
CN1635911A (zh)	2005-07-06
EE200400024A (et)	2004-06-15
WO2003000295A2 (en)	2003-01-03

Publication	Publication Date	Title
IL158765A0 (en)	2004-05-12	Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
AU2914202A (en)	2002-02-18	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AU2002230831A1 (en)	2002-04-29	Compositions of human proteins and method of use thereof
AU2002213485A1 (en)	2002-04-22	Inhibitors of protein kinases
EP1383743A4 (en)	2006-04-12	DOUBLE INHIBITORS OF PDE 7 AND PDE 4
AU2002352726A1 (en)	2003-06-10	Formulations and methods for treatment or amelioration of inflammatory conditions
AU8969601A (en)	2002-02-13	New use of lipase inhibitors
DK1216025T3 (da)	2006-10-30	Dispersionsformuleringer indeholdende lipaseinhibitorer
AU2002348276A1 (en)	2003-06-10	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
AU2002355551A1 (en)	2003-02-24	Antisense modulation of cholesteryl ester transfer protein expression
AU2003300692A1 (en)	2005-05-19	Stable formulations of ace inhibitors and methods for preparation thereof
AU2002338734A1 (en)	2003-07-03	Use of phosphorodiesterase IV inhibitors
AU2002342417A1 (en)	2002-11-25	Inhibitors of dna methyltransferase isoforms
AU2003215452A1 (en)	2003-09-09	Surface proteins of leptospira
AU1212002A (en)	2002-02-18	Use of lipase inhibitors
AU2002305868A1 (en)	2002-12-23	Inhibitors of reggamma
AU2002221882A1 (en)	2002-06-03	Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2002325827A1 (en)	2002-12-16	Compositions and methods for detecting or regulating cholesteryl ester transfer protein
AU2001293780A1 (en)	2002-03-13	Regulation of human protein phosphatase iic-like enzyme
AU2001250379A1 (en)	2001-09-24	Regulation of human diazepam binding inhibitor/acyl-coa-like protein
AU2001232734A1 (en)	2001-09-17	Compositions containing potential spla2 inhibitors for the treatment of pain
AU2002303827A1 (en)	2002-12-09	Compositions and methods for extension of nucleic acids
AU2002222472A1 (en)	2002-06-24	Backbone cyclized inhibitors of heat shock proteins
AU2002328906A1 (en)	2003-03-03	Inhibitors of polyq-aggregation
GB0125867D0 (en)	2001-12-19	Isolation of protein